The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment

• Egile Nagusiak: Lina Wu (Egilea), Wenxiong Xu (Egilea), Xuejun Li (Egilea), Ying Liu (Egilea), Lu Wang (Egilea), Shu Zhu (Egilea), Fangji Yang (Egilea), Chan Xie (Egilea), Liang Peng (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2021-02-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Sodium taurocholate cotransporting polypeptide (NTCP) acts as a cellular receptor for the hepatitis B virus infection of host hepatocytes. Previously, many studies confirmed that the NTCP p.Ser267Phe variant was a protective factor against HBV-related disease progression. We therefore designed this...